Phase 1 Endometrial Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You must be 18 years of age or older.
- You must be willing and able to sign a consent form agreeing to take part in the trial.
- You must have been diagnosed with a specific type of advanced cancer (such as non-small cell lung cancer, pancreatic cancer, colorectal cancer, or another solid tumor) that has spread or cannot be surgically removed, confirmed through a tissue sample.
- Your cancer must have been tested and confirmed to have a specific gene change called a KRAS mutation before starting the trial.
- Your cancer must have gotten worse during standard treatment, or you were unable to tolerate standard treatment.
- You must be generally well enough to carry out daily activities with little or no limitation, as measured by a standard health score (confirm with trial site).
- Your heart, blood, liver, and kidneys must be functioning well enough to meet the trial's requirements.
- Your cancer must be measurable on scans at the start of the trial, according to standard measurement guidelines.
Who may not be able to join:
- You have previously received or are currently receiving a treatment that targets the RAS or KRAS gene.
- Your cancer has spread to the brain or spinal cord, or you have a tumor in the brain.
- You are unable to swallow tablets or capsules taken by mouth.
- You are pregnant, breastfeeding, or planning to become pregnant or father a child during the trial period.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 617-612-6810
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of Participants With Dose-limiting Toxicities (DLTs) at the end of Cycle 1 (Each Cycle is 21 Days); Number of Participants With Treatment-emergent Adverse Events (TEAEs); Number of Participants With Treatment-related Adverse Events (TRAEs)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.